These experiments showed that, in NSCLC cells with varying EGFR status, BEZ235 or the combination of LY294002 and rapamycin efficiently reduced the expression of cyclin D1 and cyclin D3. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.